Written and medically reviewed by: Assoc. Prof. Cengiz Dibekoğlu, MD, General SurgeryLast updated:
Molecular Testing in Breast Cancer
ER/PR/HER2 remain foundational; germline BRCA and other genes guide drugs and risk-reducing decisions.
Every invasive breast cancer needs hormone receptor and HER2 assessment — the backbone of systemic therapy. Germline genetic testing frameworks increasingly offer BRCA1/2 evaluation to many newly diagnosed patients based on age and guidelines, with individualized decisions above certain ages. Results affect PARP-inhibitor eligibility, surgical risk-reduction choices, and relatives’ screening. Order tests that answer a stage-specific question rather than collecting unused data.
Outcomes of any surgical or interventional procedure may vary from person to person. Please seek a detailed consultation with your physician before any procedure.
© Cengiz Dibekoğlu — illustrative; not for unauthorized use
Figure summary
This educational figure shows: Breast.
Who may be a candidate?
- International patients preparing a structured second-opinion visit
- Patients comparing observation, medical care, and procedural options
Possible advantages
- Supports informed consent with alternatives and recovery themes
- Highlights red flags that should trigger urgent contact
Limits & realistic expectations
- Cannot replace examination, imaging, or pathology
- Local protocols and tumor-board decisions may refine timing
- Outcomes vary with anatomy, stage, and comorbidity
Step-by-step overview
- 1
Clarify the clinical question
What diagnosis is being confirmed and what decision follows?
- 2
Choose first-line tests
Start with the test that answers the leading question safely.
- 3
Stage if needed
Add imaging or endoscopy when results would change management.
- 4
Name limitations
No test replaces exam; false reassurance is a risk.
- 5
Link to next step
Diagnosis should point to observation, medical care, or procedure.
Key points
- Key note inside
Somatic vs germline
Tumor-only findings are not automatically hereditary. Germline counseling uses separate consent and cascade-testing rules. Discuss timing, alternatives, and follow-up with your surgical team before you finalize a plan.
- Key note inside
Important
This page is for education. It is not medical advice and does not replace a visit with your physician.
Frequently asked questions
What is the basic breast cancer panel?
ER, PR, HER2 (and Ki-67 in many contexts) guide endocrine, anti-HER2, and chemotherapy decisions.
Who is offered germline BRCA testing?
Guideline frameworks increasingly offer testing to many newly diagnosed patients by age and risk features; decisions above certain ages are individualized.
Do germline results affect surgery choices?
They can influence risk-reducing options and systemic therapy eligibility — discuss timing with your team.
Is receptor testing optional?
No. It is foundational for treatment planning in invasive breast cancer.
More chapters in this hub
Molecular Testing Overview
Biomarkers answer specific treatment and hereditary questions
Molecular Testing in Colorectal Cancer
MMR/MSI, RAS/BRAF, and selected HER2/NTRK contexts
Molecular Testing in Gastric Cancer
HER2, PD-L1, CLDN18.2, and MSI/MMR timing
Molecular Testing in Pancreatic Cancer
Germline testing is discussed for most patients; tumor profiling in advanced disease
Hereditary Cancers
Lynch, BRCA, FAP, CDH1, and genetic counseling in surgical patient language
Appointment / info
This page is for education. It is not medical advice and does not replace a visit with your physician.
Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · Last medically reviewed: August 2026 · English patient-education chapter.